# Olsen 2011 response criteria (mycosis fungoides and Sezary syndrome)

Source: https://onco.cc/terms/olsen-2011-ctcl-response/  
OnCo record `olsen-2011-ctcl-response` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

These consensus rules judge response in mycosis fungoides and Sezary syndrome across skin, lymph nodes, blood and organs, because these lymphomas behave unlike other lymphomas.

## Summary

Trials in mycosis fungoides and Sezary syndrome, the main cutaneous T-cell lymphomas, lacked standard evaluation, staging, endpoints and response criteria. A consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium and the EORTC Cutaneous Lymphoma Task Force (Olsen and colleagues, Journal of Clinical Oncology 2011) set out how trials should be run, how to assess disease in skin, lymph nodes, blood and organs, and how endpoints and response are defined.

## Fields

- Kind: Term
- Last checked: 2026-11-04
- Also known as: Olsen 2011 criteria; ISCL/EORTC response criteria; global response score

## Sources

- Olsen et al., Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement (J Clin Oncol 2011): https://doi.org/10.1200/jco.2010.32.0630

## Connected records

- terms: [Complete response (CR) and partial response (PR)](https://onco.cc/terms/complete-response-term/), [Lugano classification / Ann Arbor staging](https://onco.cc/terms/lugano-classification/)
- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/), [Mycosis fungoides](https://onco.cc/cancers/mycosis-fungoides/), [Sezary syndrome](https://onco.cc/cancers/sezary-syndrome/)

---
JSON: https://onco.cc/api/v1/entities/olsen-2011-ctcl-response.json